U. Duehrsen

发表

Interim positron emission tomography in diffuse large B-cell lymphoma.

D. Hasenclever, O. Sabri, R. Kluge, 2020, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

M. Kersten, D. Hose, H. Goldschmidt, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acquired immunodeficiency syndrome‐related lymphoma

D. Huhn, I. Anagnostopoulos, K. Arastéh, 2006, Cancer.

Pegfilgrastim primary prophylaxis in patients with non‐Hodgkin lymphoma: results from an integrated analysis

M. Schwenkglenks, R. Pettengell, P. Bacon, 2011, Hematological oncology.

Abnormal Free Light Chain Ratios are Significantly Associated with Clinical Progression in Chronic Lymphocytic Leukemia

H. Nückel, L. Sellmann, L. Eisele, 2010 .

Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas – a Randomized Controlled Trial Comparing Different Treatment Approaches Based on Interim PET Results (PETAL Trial)

W. Klapper, C. Franzius, K. Jöckel, 2014 .

Prolonged survival with improved tolerability in higher‐risk myelodysplastic syndromes: azacitidine compared with low dose ara‐C

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2010, British journal of haematology.

Darbepoetin alfa administration in patients with non-Hodgkin lymphoma and chemotherapy-induced anemia receiving (±R)CHOP

C. Haioun, G. Verhoef, P. Lugtenburg, 2013, Hematology.

Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study

A. Salar, U. Jaeger, C. Haioun, 2011, Leukemia and Lymphoma.

Dose-dependent role of Gfi1 in murine hematopoietic stem cell self-renewal and differentiation

C. Khandanpour, D. Engel, D. Frank, 2019, bioRxiv.

Acute myeloid leukemia-induced remodeling of the human bone marrow niche predicts clinical outcome.

L. Klein-Hitpass, K. Schmid, H. Hanenberg, 2018, Blood advances.

Six, Not Eight Cycles of Bi-Weekly CHOP with Rituximab (R-CHOP-14) Is the Preferred Treatment for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2005 .

Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice

A. Salar, U. Jaeger, H. Johnsen, 2012, Leukemia & lymphoma.

Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group

J. Gerss, S. Koschmieder, W. Berdel, 2010 .

The importance of G-CSF prophylaxis in R-CHOP-14 therapy for diffuse large B-cell lymphoma in routine clinical practice

A. Salar, U. Jaeger, C. Haioun, 2017 .

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

M. Kersten, H. Goldschmidt, P. Sonneveld, 2014, Haematologica.

Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas (PETAL trial): Correlation between Clinical Variables and PET Parameters.

A. Bockisch, S. Müller, A. Hüttmann, 2009 .

HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)

M. Kersten, D. Hose, H. Goldschmidt, 2010 .

Cloned stromal cell lines derived from human Whitlock/Witte-type long-term bone marrow cultures.

A. Boyd, K. Welch, J. Cebon, 1990, Experimental hematology.

Cyclophosphamide, Adriamycin, Vincristine and Prednisone Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Cytopenia (AIC) or Richter's Transformation (RT): Final Analysis of a Phase II Study of the German CLL Study Group

M. Stauch, M. Hallek, S. Stilgenbauer, 2011 .

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

M. Kersten, D. Hose, H. Goldschmidt, 2018, Leukemia.

Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial

M. Kersten, D. Hose, H. Goldschmidt, 2015 .

Six vs. Eight Cycles of Bi-Weekly CHOP-14 with or without Rituximab for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Completed RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2006 .

Autologous Stem Cell Transplantation and Addition of Rituximab Independently Prolong Response Duration in Advanced Stage Mantle Cell Lymphoma.

E. Hoster, W. Hiddemann, M. Pfreundschuh, 2009 .

Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial

M. Kersten, D. Hose, H. Goldschmidt, 2013 .

Response Adapted Assignment of the Number of Chemotherapy Cycles for the Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Is Not Justified: Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2007 .

Interim analysis of the largest prospective trial to date in adult CD20-positive post-transplant lymphoproliferative disorder (PTLD): Introducing risk-stratified sequential treatment (RSST).

J. Zaucha, P. Reinke, H. Lehmkuhl, 2012 .

The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice.

A. Salar, U. Jaeger, H. Johnsen, 2012, Leukemia research.

Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

C. Haioun, F. Morschhauser, G. Hess, 2010 .

Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas - Interim PET-Based Outcome Prediction and Treatment Changes in Patients with T Cell Lymphomas Participating in the PETAL Trial

W. Brenner, W. Klapper, C. Franzius, 2016 .

Improvement in Fatigue With Eculizumab Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria (pnh) Occurs Independent of Changes in Anemia

D. Cella, A. Zanella, A. Risitano, 2008 .

Long Term Safety and Efficacy of Sustained Eculizumab Treatment In Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

J. Maciejewski, L. Luzzatto, J. Szer, 2010 .

Phased variants improve DLBCL minimal residual disease detection at the end of therapy.

Ash A. Alizadeh, W. Wilson, C. Liu, 2021, Journal of Clinical Oncology.

Determinants of Circulating Tumor DNA Levels across Lymphoma Histologic Subtypes

Ash A. Alizadeh, W. Wilson, R. Advani, 2017 .

EFFECT OF AZACITIDINE (AZA) vs LOW-DOSE ARA-C (LDAC) ON OVERALL SURVIVAL (OS), HEMATOLOGIC RESPONSE, TRANSFUSION INDEPENDENCE, AND SAFETY IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)

H. Dombret, G. Mufti, P. Fenaux, 2008 .

Use of G-CSF in Patients with Severe Aplastic Anemia Treated with ATG and Cyclosporine Increases Neutrophils and Decreases Infection Rates and Hospitalization Days but Does Not Improve Long-Term Outcome: Results of a Prospective, Randomized Clinical Trial of the EBMT.

E. Thiel, M. Hallek, J. Passweg, 2009 .

Circulating Tumor DNA Is a Reliable Measure of Tumor Burden at Diagnosis of Diffuse Large B Cell Lymphoma: An International Reproducibility Study

Ash A. Alizadeh, W. Wilson, C. Liu, 2017 .

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

M. Kersten, D. Hose, H. Goldschmidt, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Febrile Neutropenia Risk Assessment and Granulocyte-Colony Stimulating Factor Support in Patients with Diffuse Large B Cell Lymphoma Receiving R-CHOP Regimens.

A. Salar, U. Jaeger, H. Johnsen, 2009 .